Lyra Therapeutics (Lyra Therapeutics) EBIT : $-71.74 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lyra Therapeutics EBIT?

Lyra Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-23.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-71.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lyra Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -181.05%. Lyra Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -222.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lyra Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 243.89%.

Lyra Therapeutics EBIT Historical Data

The historical data trend for Lyra Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyra Therapeutics EBIT Chart

Lyra Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-16.52

-22.21

-43.62

-54.99

-65.53

Lyra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-17.31	-14.91	-16.83	-16.48	-23.52

Competitive Comparison of Lyra Therapeutics's EBIT

For the Biotechnology subindustry, Lyra Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyra Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lyra Therapeutics's EV-to-EBIT falls into.

Lyra Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.74 Mil.

Lyra Therapeutics (NAS:LYRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lyra Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-94.096 * ( 1 - -0.06% )	/	( (46.102	+	57.907)	/ 2 )
=	-94.1524576	/	52.0045
=	-181.05 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	142.6	-	11.274	-	( 102.753	-	max(0, 19.597	-	104.821	+	102.753	))
=	46.102

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	141.527	-	12.901	-	( 87.118	-	max(0, 18.724	-	89.443	+	87.118	))
=	57.907

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Lyra Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-94.096	/	( ( (35.276 + max(-12.095, 0))	+	(49.409 + max(-11.895, 0)) )	/	2 )
=	-94.096	/	( ( 35.276	+	49.409 )	/	2 )
=	-94.096	/	42.3425
=	-222.23 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.068)	-	(11.274	+	1.658	+	1.231)
=	-12.095

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.325)	-	(12.901	+	1.319	+	0)
=	-11.895

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lyra Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-71.739	/	-29.414
	=	243.89 %

Lyra Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Lyra Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyra Therapeutics (Lyra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyra Therapeutics Inc (NAS:LYRA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Watertown, MA, USA, 02472

Website

https://lyratherapeutics.com

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Executives

Harlan Waksal	director, officer: Executive Chair	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nbvm Gp, Llc	10 percent owner	950 WINTER STREET, SUITE 4600, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Edward T Anderson	director, 10 percent owner	950 WINTER ST SUITE 4600, WATHAM MA 02451
John E Bishop	officer: Chief Technology Officer	675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Richard Nieman	officer: Chief Medical Officer	C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
C Ann Merrifield	director
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jason Cavalier	officer: Chief Financial Officer	C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Pamela E. Nelson	officer: Senior VP, Regulatory Affairs	C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Robert E. Richard	officer: SVP of R&D	C10 LYRA THERAPEUTICS, INC., 1480 ALSENAL WAY, WATERTOWN MA 02472
Soleus Private Equity Fund I, L.p.	10 percent owner	C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Soleus Capital, Llc	10 percent owner	104 FIELD POINT ROAD, FLOOR 2, GREENWICH CT 06830
Polaris Venture Partners Special Founders' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210